<DOC>
	<DOCNO>NCT00788541</DOCNO>
	<brief_summary>The purpose study assess effect total volume total dose safety intraocular pressure-lowering efficacy Anecortave Acetate Suspension ( 3 mg 48 mg ) 0.5 mL 0.8 mL volume administer anterior juxtascleral depot ( AJD ) treatment elevate intraocular pressure ( IOP ) patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>A Dose-Volume Study Treatment Elevated IOP Due Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Clinical diagnosis OpenAngle Glaucoma Ocular Hypertension least 6 month ; Other protocoldefined inclusion criterion may apply . Prior angle surgery study eye , severe visual field loss either eye ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Intraocular Pressure</keyword>
	<keyword>Anecortave Acetate</keyword>
</DOC>